SCHEMBL683558

SCHEMBL683558

CC(=O)c1c(C)nn2cccc(O)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
ALDH1A1 P00352 4/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KDM4E B2RXH2 1/20 0.40
POLB P06746 3/20 0.38
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
PDE4D Q08499 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NT5E P21589 1/20 0.34
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7373297 0.85 POLB (0.39) THRBALDH1A1KMT2AHSD17B10POLB
SCHEMBL683499 0.83 POLB (0.38) ALDH1A1KMT2AHSD17B10POLBMAPT
SCHEMBL682711 0.80 GAA (0.40) ALDH1A1KMT2AHSD17B10RAB9AL3MBTL1
SCHEMBL683860 0.79 ALDH1A1 (0.37) ALDH1A1KMT2AHSD17B10KDM4EPOLB
SCHEMBL5848990 0.73 ALDH1A1 (0.51) ALDH1A1KMT2AHSD17B10KDM4EPOLB
SCHEMBL31131637 0.73 FYN (0.38) THRB
SCHEMBL17867572 0.71 NTRK1 (0.39) ALDH1A1KMT2AKDM4EPOLBMAPT
SCHEMBL3265389 0.71 POLB (0.44) KMT2AKDM4EPOLBMAPTRAB9A
SCHEMBL20669696 0.69 PIK3CG (0.51) ALDH1A1KMT2AHSD17B10KDM4ERAB9A
SCHEMBL11657180 0.68 PDE4B (0.49) ALDH1A1KMT2AKDM4ERAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF THRB 2127/4885ALDH1A1 1565/4885KMT2A 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.